World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 16 December 2017
Main ID:  NCT00290628
Date of registration: 09/02/2006
Prospective Registration: No
Primary sponsor: Masonic Cancer Center, University of Minnesota
Public title: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Scientific title: Transplantation of Umbilical Cord Blood From Related and Unrelated Donors
Date of first enrolment: October 1999
Target sample size: 43
Recruitment status: Terminated
Study type:  Interventional
Study design:  Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  N/A
Countries of recruitment
United States
Name:     John E. Wagner, MD
Affiliation:  Masonic Cancer Center, University of Minnesota
Key inclusion & exclusion criteria


- Diagnosis of 1 of the following:

- Leukemia including, but not limited to, the following subtypes:

- Chronic myelogenous leukemia

- Acute myeloid leukemia (primary or secondary)

- Acute lymphoblastic leukemia

- Lymphoma

- Myelodysplastic syndrome

- Aplastic anemia

- Fanconi's anemia

- Diamond-Blackfan anemia

- Inborn errors of metabolism (e.g., Hurler syndrome, Maroteaux-Lamy syndrome,
myelodysplastic syndrome VI, metachromatic leukodystrophy, adrenoleukodystrophy,
and globoid cell leukodystrophy)

- Immune deficiency disorders

- Patients must meet the eligibility requirements outlined in currently active treatment
protocols of the University of Minnesota Bone Marrow Transplant Program

- HLA-identical or 1, 2, or 3 antigen mismatched umbilical cord blood (UCB) donor with
at least one DRB1 match available

- Unrelated or related donor

- UCB specimen must contain = 2.0 x 10^7 nucleated cells/kg patient body weight


- See Disease Characteristics

- No active infection

- No history of HIV infection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception


- Not specified

Age minimum: N/A
Age maximum: 45 Years
Gender: All
Health Condition(s) or Problem(s) studied
Chronic Myeloproliferative Disorders
Diamond-blackfan Anemia
Fanconi Anemia
Graft Versus Host Disease
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Diseases
Drug: anti-thymocyte globulin
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: filgrastim
Drug: melphalan
Drug: methylprednisolone
Drug: mycophenolate mofetil
Procedure: radiation therapy
Procedure: umbilical cord blood transplantation
Primary Outcome(s)
Secondary Outcome(s)
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
National Cancer Institute (NCI)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history